Clinical Trials Directory

Trials / Unknown

UnknownNCT03869255

Nasal Carrying by Staphylococcus Aureus ST398 Strains in Community and Hospital Settings

Status
Unknown
Phase
Study type
Observational
Enrollment
2,000 (estimated)
Sponsor
Centre Hospitalier Universitaire de Besancon · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The aim of this study was to compare the prevalence of nasal carrying of SA ST398 strains in community and hospital settings, identify the factors associated with colonization of SA ST398, determine the distribution of imported and acquired cases among SA ST398 hospital cases and characterize the genetic structure of the ST398 SA population involved in colonization.

Detailed description

Staphylococcus aureus (SA) is a ubiquitous bacterium, part of the human commensal flora. The mucosa of the anterior nasal cavities represents the preferred site of colonization of SA. The SA ST398 clone, belonging to CC 398, was initially described as a zoonotic agent initially identified in France and the Netherlands. In fact, ST398 strains are separated into two distinct populations: a methicillin-resistant SA population (SAMR) with notion of contact with animals and a more virulent methicillin-sensitive SA population (SAMS) than its counterpart, isolated from serious human infections and without notion of exposure to farm animals. Recently, we have shown that, in SA bacteremia, all strains of SA ST398 are sensitive to methicillin and that the prevalence of ST398 among all SAMS responsible for bacteremia at Besançon University Hospital increased between 2009 and 2014, increased from 4 to 15%. However, we were unable to study nasal colonization to support the mode of acquisition of SA ST398 (community vs. healthcare acquisition).

Conditions

Interventions

TypeNameDescription
PROCEDURENasal swabIn hospitalized patiens, a nasal swab will be performed within the first 48 hours and on the 7th day. In community patient, only one swab will be performed

Timeline

Start date
2019-04-01
Primary completion
2020-04-01
Completion
2020-09-01
First posted
2019-03-11
Last updated
2019-03-11

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT03869255. Inclusion in this directory is not an endorsement.